MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck(AstraZeneca (Australia)), Anthony J. Coyle(Immune Regulation (United Kingdom)), Néstor A. Molfino(Amgen (United States)), Geoffrey L. Stephens(Institute of Neuroimmunology of the Slovak Academy of Sciences), Leif Bjermer(Lund University), Jonas S. Erjefält(Lund University), Alison A. Humbles(Institute of Neuroimmunology of the Slovak Academy of Sciences), David Gossage, Cecilia Andersson(Lund University), Herren Wu, Charles R. Mackay(Discovery Institute), Peng Li, Melissa Damschroder(AstraZeneca (Brazil)), Robert M. Woods, Masamichi Koike(Princeton University), Peter A. Kiener(Institute of Neuroimmunology of the Slovak Academy of Sciences), Alexander Kozhich(Institute of Neuroimmunology of the Slovak Academy of Sciences), Jennifer L. Reed(University of Ottawa), George L. Spitalny(Princeton University), William W. Dall'Acqua
Cited by 578
Related Papers
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
|CHEST Journal|2016|426
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329
Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD 2–4)
|European Respiratory Journal|2015|322
Evidence of Airway Inflammation and Remodeling in Ski Athletes with and without Bronchial Hyperresponsiveness to Methacholine
|American Journal of Respiratory and Critical Care Medicine|2000|319